Earnings Call · Q4 FY2025·2026-02-26

Q4 25EPS +46.34%·Rev n/aQ3 25EPS +21.43%·Rev n/aQ2 25EPS +7.69%·Rev n/aQ1 25EPS +32.61%·Rev n/a⚠ consensus missing

NovoCure Ltd NVCR

Adam Daney — Head of Investor Relations

William Doyle — Executive Chairman

Frank Leonard — CEO

Christoph Brackmann — CFO

−1.2%1d on move date−1.3% vs SPY3d−4.0%5d−4.9%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NVCR calls or request research access.

More NVCR calls Browse calls Request research access